Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 MutationsAlessandra Bearz, Jean-François Martini, Jacek Jassem, et al.
The Lancet. Oncology|May 14, 2018
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trialVanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, et al.
BJU International|May 24, 2011
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesCamillo Porta, Giuseppe Procopio, Giacomo Cartenì, et al.
Current HIV Research|February 18, 2010
Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infectionMassimiliano Berretta, Arben Lleshi, Alessandro Cappellani, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
The Oncologist|August 27, 2011
Hepatocellular carcinoma in HIV-infected patients: check early, treat hardMassimiliano Berretta, Elisa Garlassi, Bruno Cacopardo, et al.
European Urology Oncology|September 23, 2019
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT StudyGiuseppe Procopio, Giulia Apollonio, Francesco Cognetti, et al.
Clinical Pharmacokinetics|December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung CancerJoseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.
The Lancet. Oncology|July 22, 2017
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trialMichele Maio, Arnaud Scherpereel, Luana Calabrò, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trialAntonio Santo, Sara Pilotto, Domenico Galetta, et al.
Pageof 12